Pacira Biosciences Inc PCRX:NASDAQ

Last Price$58.35NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/07/20

Today's Change+0.22(0.38%)
Bid (Size)$58.35 (13)
Ask (Size)$58.47 (1)
Day Low / High$57.38 - 58.75
Volume637.8 K
 

View Pharmaceuticals: Other IndustryPeer Comparison as of 08/07/2020

 

Pacira Biosciences Inc ( NASDAQ )

Price: $58.35
Change: +0.22 (0.38%)
Volume: 637.8 K
4:00PM ET 8/07/2020
 
 

SAGE Therapeutics Inc ( NASDAQ )

Price: $50.70
Change: +0.70 (1.40%)
Volume: 645.9 K
4:00PM ET 8/07/2020
 
 

Axsome Therapeutics Inc ( NASDAQ )

Price: $78.07
Change: +0.03 (0.04%)
Volume: 395.7 K
4:00PM ET 8/07/2020
 
 

Prestige Consumer Healthcare Inc ( NYSE )

Price: $39.94
Change: -0.85 (2.08%)
Volume: 340.9 K
7:00PM ET 8/07/2020
 
 

Revance Therapeutics Inc ( NASDAQ )

Price: $26.06
Change: +2.48 (10.52%)
Volume: 1.1 M
4:00PM ET 8/07/2020
 

Read more news Recent News

Consensus for Pacira Biosciences Q3 and 2021 Outlook Increased
10:05AM ET 8/08/2020 MT Newswires

The September 30, 2020 quarterly, and December 31, 2021 full year earnings estimates for Pacira Biosciences Inc (NASDAQ:PCRX, Recent Price: 58.35) have...

Pacira Biosciences' 2021 Earnings Estimate Bumped Up
10:50AM ET 8/07/2020 MT Newswires

Pacira Biosciences Inc's (NASDAQ:PCRX, Recent Price: 58.13) 2021 forecasted earnings estimate for the year ending December 31, 2021 has been increased. The...

--Analyst Actions: RBC Capital Lifts Price Target on Pacira BioSciences to $65 From $63, Maintains Outperform Rating
8:43AM ET 8/07/2020 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Pacira Biosciences' Q2 Estimate Raised but 2021 Outlook Decreased
8:20AM ET 8/06/2020 MT Newswires

The June 30, 2020 quarterly, and December 31, 2021 full year earnings estimates for Pacira Biosciences Inc (NASDAQ:PCRX, Recent Price: 56.10) have been...

Company Profile

Business DescriptionPacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ. View company web site for more details
Address5 Sylvan Way
Parsippany, New Jersey 07054
Phone+1.973.254.3560
Number of Employees518
Recent SEC Filing08/06/202010-Q
Chairman, Chief Executive & Operating OfficerDavid M. Stack
Chief Financial OfficerCharles A. Reinhart
Vice President-Research & DevelopmentVladimir Kharitonov
Chief Technology OfficerCharles Anthony Laranjeira

Company Highlights

Price Open$58.14
Previous Close$58.35
52 Week Range$27.46 - 59.93
Market Capitalization$2.5 B
Shares Outstanding42.7 M
SectorHealth Technology
IndustryPharmaceuticals: Other
Next Earnings Announcement11/05/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share$0.16
Beta vs. S&P 500N/A
Revenue$337.3 M
Net Profit Margin-2.47%
Return on Equity-2.76%

Analyst Ratings as of 07/10/2020

Buy
9
Overweight
0
Hold
5
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset